GSK, Novartis Downplay Pfizer/Pharmacia: New Themes For “Critical Mass”?
Executive Summary
The Pfizer/Pharmacia merger will not fundamentally change the pharmaceutical industry dynamics unless Pfizer sheds product lines to concentrate greater resources behind key brands, Novartis and GSK argued in separate investor presentations